Federal Circuit Affirms Board Finding That Exclusion of Genus Does Not Provide Written Description For Exclusion of Species

30 July 2013 PharmaPatents Blog

In In Re Bimeda Research & Development Ltd., the Federal Circuit upheld the decision of the USPTO Patent Trial and Appeal Board (PTAB) that found that a claim that excluded the presence of a specific compound was not supported by a description that excluded a genus of compounds. This case illustrates the challenges of establishing written description for exclusion of specific embodiments.

The Patent at Issue

The patent at issue was Bimeda’s U.S. Patent 6,506,400, which was undergoing ex parte reexamination. The patent is directed to compositions for preventing bovine mastitis by providing a physical barrier within the teat canal to block mastitis-causing organisms. As noted by the Federal Circuit, the patent emphasized that it did not require the use of antiinfective agents such as antibiotics.

Claim 1 as originally granted recited:

A prophylactic method of controlling infection in a mammary gland by a mastitis-causing organism, comprising sealing a teat canal of a mammary gland with a seal formulation so as to provide a physical barrier in the teat canal.

The claims at issue recited that the teat seal canal had an “acriflavine-free” formulation.

The PTAB Decision 

The acriflavine claims were rejected under 35 USC § 112, ¶ 1, for lack of written description. As summarized by the Federal Circuit, the Examiner “reasoned  that ‘acriflavine’ was not mentioned anywhere in the original disclosure of the ’400 patent and so therefore the disclosure did not demonstrate possession of an acriflavine-free composition.” The Examiner also explained that “the ’400 patent’s disclosure failed to describe formulations which … could exclude acriflavine but include other antiinfectives.” 

[T]he specific exclusion of acriflavine introduces a new concept, as [it] implies inclusion of one or more undisclosed antiinfectives other than acriflavine. Such a concept is not supported in the disclosure as originally filed.

The Board affirmed the Examiner’s rejection, agreeing that the specification “failed to demonstrate possession of a formulation that specifically excluded the acriflavine species of antiinfectives,” or possession of ”a formulation which excluded acriflavine but could include other antiinfective agents.”

The Federal Circuit Decision 

Judge Clevenger wrote the opinion for the court, which was joined by Judge Prost. Chief Judge Rader wrote a concurring opinion.

The court upheld the PTAB decision:

Substantial evidence supports the [PTAB decision] because the disclosure is generally inconsistent with a formulation which … excludes acriflavine but could include antibiotics.

The court noted that the specification emphasized the “antibiotic-free” approach of the invention and agreed with the Board that “the ’400 patent’s disclosure is … inconsistent with a claim which “excludes acriflavine, but not the presence of other anti-infectives or antibiotics.”

Chief Judge Rader’s Concurrence

While joining the court’s decision, Chief Judge Rader criticized the PTAB’s focus on a traditional written description “possession” analysis rather than “wrestl[ing] with the fact that the claim at issue (and the patent as a whole) focuses on negative claiming.” 

[T]he specification clearly supports a formulation which excludes all antiinfectives. Acriflavine was a well-known species of antiinfective that had been used in teat seals to treat bovine mastitis for over 75 years. … Some of the Board’s analysis of possession ignored these facts and ignored the nature of the claims.

The Difficulty of Negative Claiming 

This case illustrates the difficulty of negative claiming. Unless the original specification describes specific carve-outs, an Applicant’s ability to exclude specific subject matter from the claims is limited. One quirk of U.S. patent law is that an Applicant can exclude components or steps that are described as optional, in accordance with MPEP § 2173.05(i). Thus, for example, if Bimeda’s application had stated that acriflavine optionally can be included in its compositions, it would have been able to specifically exclude acriflavine without running afoul of the written description requirement. Perhaps this rule explains the PTAB analysis that troubled Chief Judge Rader.

This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney. This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary. The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites. In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.

Related Services


Foley Automotive Report
27 September 2022
Dashboard Insights
Type C Patent Term Adjustment Requires Fully Successful Appeal
27 September 2022
The SEC Signals it is Ready to Enforce the New Marketing Rules
26 September 2022
Foley Funds Legal Focus
More Cuts to NYC’s COVID-19 Restrictions
26 September 2022
Labor & Employment Law Perspectives
Foley Sponsors Ernst & Young Entrepreneur of the Year® Program
1 December 2021 - 30 November 2022
Michigan and Northwest Ohio Region
County Counsels’ Association of California Health & Welfare Fall 2022 Study Section Spring Meeting
18 November 2022
Santa Rosa, CA
Moss Adams 2022 Health Care Conference
3-4 November 2022
Las Vegas, NV
An Update on Remote Patient Monitoring Policy and Reimbursement
28 October 2022
Austin, TX